González de Aledo, M.; González-Bardanca, M.; Blasco, L.; Pacios, O.; Bleriot, I.; Fernández-García, L.; Fernández-Quejo, M.; López, M.; Bou, G.; Tomás, M.
CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies. Antibiotics 2021, 10, 756.
https://doi.org/10.3390/antibiotics10070756
AMA Style
González de Aledo M, González-Bardanca M, Blasco L, Pacios O, Bleriot I, Fernández-García L, Fernández-Quejo M, López M, Bou G, Tomás M.
CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies. Antibiotics. 2021; 10(7):756.
https://doi.org/10.3390/antibiotics10070756
Chicago/Turabian Style
González de Aledo, Manuel, Mónica González-Bardanca, Lucía Blasco, Olga Pacios, Inés Bleriot, Laura Fernández-García, Melisa Fernández-Quejo, María López, Germán Bou, and María Tomás.
2021. "CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies" Antibiotics 10, no. 7: 756.
https://doi.org/10.3390/antibiotics10070756
APA Style
González de Aledo, M., González-Bardanca, M., Blasco, L., Pacios, O., Bleriot, I., Fernández-García, L., Fernández-Quejo, M., López, M., Bou, G., & Tomás, M.
(2021). CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies. Antibiotics, 10(7), 756.
https://doi.org/10.3390/antibiotics10070756